Background and Objective: Cancer being an abnormal group of cells which invade or spread
throughout the organ/body. It is either a result of genetic mutation or gene mutation due to life
style change, sometimes an involuntary exposure to environmental factors likely harmful
radiations, cigarette smokes, medicines/drugs, pollution, and many more. Inherited genetic
mutations play a major role in about 5-10 percent of all cancers, while the remaining 90-95
percent have their origin in environmental factors and lifestyle changes. In recent years,
increased mushroom consumption has lowered the risk of cancer. Mushrooms have protective
elements like folic acid, selenium, B vitamins such a niacin, riboflavin and pantothenic acid,
copper, some amounts of phosphorus, zinc, potassium, antioxidants and many more bioactive
compounds are used in adjuvant cancer treatments due to their anticarcinogenic or anti-tumor
effects. However, are the mushrooms used in treatment safe for consumer usage?
Methods: Herein, we are to find if the mushrooms used are safe for usage as dietary
supplements, adjuvants and their treatment process. Also, we are to use the MEGA 11 tool to
identify the DNA fingerprint of the mushrooms.
Result: Herein, we have presented some research studies conducted in various places using the
mushrooms like Ganoderma, Phellinus and Pleurotus species. This also focus on those individual
bioactive compounds found in the extracts of the mushrooms and how they work together with
chemotherapy to reduce cancer risk. Also, we have used the 18S cDNA sequence of our study to
identify the evolutionary taxa, DNA and protein sequence of the mushrooms with the help of
MEGA 11 software.
Novelty: The study revealed the modern adjuvant treatments used in recent years in inhibiting
the cancer cell proliferation. Also, the usage of insilico tools/softwares to identify the species
which are milled/dried/extracted.
Keywords: Adjuvant cancer treatments, cancer, mutation, mushrooms, prevention, species
identification
Publication date: 01/12/2021
https://ijbpas.com/pdf/2021/December/MS_IJBPAS_2021_DEC_SPCL_2044.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.12.2044
